[Comparative treatment between thalidomide and transfer factor in severe atopic dermatitis].
OBJECTIVE
The atopic dermatitis is an chronic inflammatory illness of the skin. It exists an interrelation complex of factors gene, environmental, and psychological that contribute to the development and severity of the illness. The immunol aberrations significant is the answer increased of IgE specific antibodies toward antigens common, the liberation is increased of immunol mediators by the basophils and mast cells, eosinophils peripheral and local, besides enlarges the biphasic activity Th1/Th2 with liberation of cytokines (IL-4, IL-5, IL-13), GM-C5F, and decrease of IFN-gamma by the cells Th1. Leung to report a knowledge upon the bases immunopathologies of it atopic dermatitis has immunopathologies clinical important for the diagnosis and processing. Alternatives multiples of processing by the same complexity of the illness exist.


OBJECTIVE
To compare the security and the clinical efficacy of the thalidomide and the factor of transfer in the atopic dermatitis severe.


METHODS
Were studied patient with diagnosis of atopic dermatitis severe in agreement with the criterions of Hanifin and Rajka that they entered to the service of Allergy and Immunology Clinical of the Hospital Regional Lic. Adolfo López Mateos (public hospital). They were included 19 patient (women 12 and men 7, with age average 30 +/- 4 years). They were distributed in two groups. The first group of 5 patient administration thalidomide 200 mg/d during six months. The second group am administered the factor of transfer a total of 15 units by road oral during six months. Studies of laboratory for appraisal were requested immunology and metabolic pretreatment and pretreatment.


RESULTS
In the group A dealt with thalidomide 5 patient and the group B dealt with FT, both presented a statistically significant decrease, as for the extension of the wounds (p < 0.01), and 1 am observed greater reduction in the intensity of the symptoms, the SCORAD total (p < 0.001 and p < 0.001 respectively) with statistical difference among them. None presented alterations immunologies and metabolic secondary to the use of the two drugs and not there was the need to suspend the processing. During the period of study, the patient were maintained controlled to the allergic rhinitis and the asthma.


CONCLUSIONS
In the atopic dermatitis by its secondary clinical complexity to the multifactors etiologic, the alternatives of processing utilized in the present study are an option the security and efficacy, I am observed better clinical.
Sosa
M
M
Servicio de alergia e inmunología clínica, Hospital Regional Lic. Adolfo López Mateos, ISSSTE, Av. Universidad 1321-colonia Florida 01030 México, DF.
Flores
G
G
Estrada
S
S
Orea
M
M
Gómez Vera
J
J
D000328:Adult; D003876:Dermatitis, Atopic / Q000628:therapy*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008800:Mexico; D013792:Thalidomide / Q000627:therapeutic use*; D014165:Transfer Factor / Q000627:therapeutic use*
D003879:Dermatologic Agents; D014165:Transfer Factor; D013792:Thalidomide